BioWorld

May 15, 2008

Amarin Adds $28M to Support CNS, Cardiovascular Pipeline

Amarin Corp. plc, which rebounded from dismal Huntington's disease data with the December acquisition of Ester Neurosciences Ltd., is moving full steam ahead once again, thanks to a $28 million cash infusion. (BioWorld Today) Read More

Wall Street Analysts Prepare for ASCO Flood Starting Friday

ApoD: Is it Toxic, Or a Life-Extender?

Lawmakers Debate FDA Liability Preemption Rules

FDA Places Hold on Geron's Cell Therapy, CEO 'Disappointed'

Other News To Note

U.S. Patent Disclosures

Clinic Roundup

Earnings Roundup

Today's news in brief

BioWorld

BioWorld briefs for Aug. 19, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Aug. 19, 2025.

CSL to shave off 3,000 jobs, Seqirus vaccine unit

BioWorld

CSL Ltd.’s stock tumbled 16.88% on the news that it plans to cut 3,000 jobs and to hive off its Seqirus vaccine unit in a cost-cutting measure to save more than...

Handshake with dollar sign and checkmark

Skyhawk’s small-molecule RNA efforts draw Merck KGaA in $2B deal

BioWorld

Adding another name to an impressive roster of partners assembled over the past few years, Skyhawk Therapeutics Inc. inked a neurology-focused deal with Merck...

Woman measuring her body fat with caliper

GI blow: Viking soldiers on with midstage oral obesity bid

BioWorld

Rates of adverse events (AEs) gave pause to some on Wall Street, and shares of Viking Therapeutics Inc. (NASDAQ:VKTX) fell 42%, or $17.73, to close Aug. 19 at...